Notification

🚨 Trading Holiday 🚨

The NSE and BSE will remain closed for trading and settlement on Monday, April 14, 2025, on account of Dr. B. R. Ambedkar Jayanti.

Open a Free Demat Account

Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.

Trade Now, Pay Later with up to 4x

Never miss a good trading opportunity due to low funds with our MTF feature.

Track Market Movers Instantly

Stay updated with real-time data. Get insights at your fingertips.

NSE BSE

Trade Nowopens in a new tab

Makers Laboratories Ltd. Share Price

₹ 141.8 4.50 (3.27%)

Apr 15 2025 03:14 PM Pharmaceuticals NSE: MAKERSL

Makers Laboratories Ltd. Share Price Update

As of the latest trading session, Makers Laboratories Ltd. share price is currently at 141.8, which is up by 4.50 from its previous closing. Today, the stock has fluctuated between 138.00 and 142.00. Over the past year, Makers Laboratories Ltd. has achieved a return of 5.33 %. In the last month alone, the return has been 0.58 %. Read More...

Makers Laboratories Ltd. Performance

Day Range

Low138.00 High142.00

141.80

52 Week Range

Low 114.00 High 230.00

141.80

Makers Laboratories Ltd. Share Price

506919

MAKERSL

Compare to down-arrow

View

Display

Studies

No Data Available

Open Price

138.95 Prev. Close

137.30 Volume (Shares)

660.00 Total traded value

.93

Upper Circuit

170.15 Lower Circuit

113.45

Note: The current prices & values are delayed, Loginopens in a new tab to your account for live updates.

Makers Laboratories Ltd. Fundamentals

(Standalone)

Market Cap (Cr)	83.66
PE Ratio (TTM)	18.07
Book Value / Share	98.79
Beta	0.19

ROE	-12.67%
EPS (TTM)	7.60
Dividend Yield	0.00%
Net Profit Qtr (Cr)	-0.77

Makers Laboratories Ltd. Financials

Key Results
Key Ratios
Balance sheet
Cash Flow
Competition

Revenue

Net income

Particulars	DEC 2024 (Values in Cr)
Revenue	9.45
Operating Expense	10.87
Net Profit	-0.77
Net Profit Margin (%)	-8.14
Earnings Per Share (EPS)	-1.31
EBITDA	0.01
Effective Tax Rate (%)	9.41

Particulars	SEP 2024 (Values in Cr)
Revenue	11.50
Operating Expense	12.71
Net Profit	8.03
Net Profit Margin (%)	69.82
Earnings Per Share (EPS)	13.62
EBITDA	10.02
Effective Tax Rate (%)	10.57

Particulars	JUN 2024 (Values in Cr)
Revenue	12.29
Operating Expense	13.66
Net Profit	-1.22
Net Profit Margin (%)	-9.92
Earnings Per Share (EPS)	-2.07
EBITDA	-0.14
Effective Tax Rate (%)	1.61

Particulars	MAR 2024 (Values in Cr)
Revenue	11.45
Operating Expense	12.73
Net Profit	-1.56
Net Profit Margin (%)	-13.62
Earnings Per Share (EPS)	-2.64
EBITDA	0.00
Effective Tax Rate (%)	-36.84

Particulars	DEC 2023 (Values in Cr)
Revenue	11.17
Operating Expense	13.39
Net Profit	-1.95
Net Profit Margin (%)	-17.45
Earnings Per Share (EPS)	-3.30
EBITDA	-1.00
Effective Tax Rate (%)	7.14

Particulars	MAR 2024 (Values in Cr)
Revenue	49.09
Operating Expense	57.19
Net Profit	-6.95
Net Profit Margin (%)	-14.15
Earnings Per Share (EPS)	-11.78
EBITDA	-2.62
Effective Tax Rate (%)	0.14

Particulars	MAR 2023 (Values in Cr)
Revenue	42.55
Operating Expense	50.46
Net Profit	-6.36
Net Profit Margin (%)	-14.94
Earnings Per Share (EPS)	-10.58
EBITDA	-3.00
Effective Tax Rate (%)	6.04

Particulars	MAR 2022 (Values in Cr)
Revenue	52.38
Operating Expense	52.92
Net Profit	0.17
Net Profit Margin (%)	0.32
Earnings Per Share (EPS)	0.35
EBITDA	3.90
Effective Tax Rate (%)	45.16

Particulars	MAR 2021 (Values in Cr)
Revenue	44.41
Operating Expense	46.90
Net Profit	-1.62
Net Profit Margin (%)	-3.64
Earnings Per Share (EPS)	-3.29
EBITDA	3.72
Effective Tax Rate (%)	22.22

Particulars	MAR 2020 (Values in Cr)
Revenue	51.40
Operating Expense	51.37
Net Profit	-0.12
Net Profit Margin (%)	-0.23
Earnings Per Share (EPS)	-0.25
EBITDA	2.94
Effective Tax Rate (%)	148.00

Particulars	MAR 2024 (Values in Cr)
Book Value / Share	106.85
ROE %	-7.27
ROCE %	-2.19
Total Debt to Total Equity	0.29
EBITDA Margin	2.54

Particulars	MAR 2023 (Values in Cr)
Book Value / Share	117.28
ROE %	-3.40
ROCE %	1.60
Total Debt to Total Equity	0.31
EBITDA Margin	5.53

Particulars	MAR 2022 (Values in Cr)
Book Value / Share	121.17
ROE %	20.61
ROCE %	22.06
Total Debt to Total Equity	0.38
EBITDA Margin	16.86

Particulars	MAR 2021 (Values in Cr)
Book Value / Share	110.08
ROE %	2.49
ROCE %	5.96
Total Debt to Total Equity	0.38
EBITDA Margin	13.23

Particulars	MAR 2024 (Values in Cr)
Book Value / Share	87.19
ROE %	-12.67
ROCE %	-7.69
Total Debt to Total Equity	0.24
EBITDA Margin	-5.32

Particulars	MAR 2023 (Values in Cr)
Book Value / Share	98.78
ROE %	-11.71
ROCE %	-7.67
Total Debt to Total Equity	0.28
EBITDA Margin	-7.05

Particulars	MAR 2022 (Values in Cr)
Book Value / Share	102.30
ROE %	0.42
ROCE %	3.01
Total Debt to Total Equity	0.35
EBITDA Margin	7.54

Particulars	MAR 2021 (Values in Cr)
Book Value / Share	100.92
ROE %	-3.44
ROCE %	-0.78
Total Debt to Total Equity	0.31
EBITDA Margin	8.38

Particulars	MAR 2020 (Values in Cr)
Book Value / Share	90.74
ROE %	-0.28
ROCE %	1.79
Total Debt to Total Equity	0.23
EBITDA Margin	5.72

Particulars	MAR 2024 (Values in Cr)
Cash & Short Term Investments	2.23
Total Assets	161.25
Total Liabilities	161.25
Total Equity	104.33
Share Outstanding	5900376
Price to Book Ratio	1.29
Return on Assets (%)	-3.88
Return on Capital (%)	-5.13

Particulars	MAR 2023 (Values in Cr)
Cash & Short Term Investments	4.36
Total Assets	152.29
Total Liabilities	152.29
Total Equity	109.67
Share Outstanding	5900376
Price to Book Ratio	0.99
Return on Assets (%)	-3.11
Return on Capital (%)	-3.92

Particulars	MAR 2022 (Values in Cr)
Cash & Short Term Investments	8.67
Total Assets	144.33
Total Liabilities	144.33
Total Equity	98.09
Share Outstanding	4916980
Price to Book Ratio	1.78
Return on Assets (%)	3.44
Return on Capital (%)	4.32

Particulars	MAR 2021 (Values in Cr)
Cash & Short Term Investments	6.21
Total Assets	136.19
Total Liabilities	136.19
Total Equity	86.57
Share Outstanding	4916980
Price to Book Ratio	2.37
Return on Assets (%)	-0.24
Return on Capital (%)	-0.33

Particulars	MAR 2024 (Values in Cr)
Cash & Short Term Investments	0.07
Total Assets	86.14
Total Liabilities	86.14
Total Equity	51.44
Share Outstanding	5900376
Price to Book Ratio	1.29
Return on Assets (%)	-8.06
Return on Capital (%)	-10.69

Particulars	MAR 2023 (Values in Cr)
Cash & Short Term Investments	0.07
Total Assets	84.79
Total Liabilities	84.79
Total Equity	58.28
Share Outstanding	5900376
Price to Book Ratio	0.99
Return on Assets (%)	-7.50
Return on Capital (%)	-9.42

Particulars	MAR 2022 (Values in Cr)
Cash & Short Term Investments	0.13
Total Assets	85.48
Total Liabilities	85.48
Total Equity	50.30
Share Outstanding	4916980
Price to Book Ratio	1.78
Return on Assets (%)	0.20
Return on Capital (%)	0.25

Particulars	MAR 2021 (Values in Cr)
Cash & Short Term Investments	0.34
Total Assets	79.11
Total Liabilities	79.11
Total Equity	49.62
Share Outstanding	4916980
Price to Book Ratio	2.37
Return on Assets (%)	-2.04
Return on Capital (%)	-2.55

Particulars	MAR 2020 (Values in Cr)
Cash & Short Term Investments	0.96
Total Assets	73.87
Total Liabilities	73.87
Total Equity	44.61
Share Outstanding	4916980
Price to Book Ratio	0.33
Return on Assets (%)	-0.16
Return on Capital (%)	-0.23

Particulars	MAR 2024 (Values in Cr)
Net Income	-6.95
Cash from Operations	-2.74
Cash from Investing	-2.03
Cash from Financing	5.11
Net change in Cash	0.01
Free Cash Flow	-0.04

Particulars	MAR 2023 (Values in Cr)
Net Income	-6.77
Cash from Operations	-1.02
Cash from Investing	-3.55
Cash from Financing	4.93
Net change in Cash	-0.03
Free Cash Flow	3.45

Particulars	MAR 2022 (Values in Cr)
Net Income	0.31
Cash from Operations	7.35
Cash from Investing	-8.78
Cash from Financing	1.76
Net change in Cash	-0.20
Free Cash Flow	18.44

Particulars	MAR 2021 (Values in Cr)
Net Income	-2.07
Cash from Operations	2.04
Cash from Investing	-2.64
Cash from Financing	1.37
Net change in Cash	-0.61
Free Cash Flow	3.48

Particulars	MAR 2020 (Values in Cr)
Net Income	0.24
Cash from Operations	4.26
Cash from Investing	-8.42
Cash from Financing	2.90
Net change in Cash	-1.29
Free Cash Flow	12.85

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L	37.65	20.24	2.05	288.52	34.11 / 77.70
BLISS GVS PHARMA LTD	119.05	15.60	1.24	1254.43	92.25 / 184.95
CIPLA LTD	1463.15	23.68	4.16	118166.50	1310.05 / 1702.00
FERMENTA BIOTECH LIMITED	264.10	21.88	2.67	777.27	145.00 / 449.00

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L	37.65	22.68	6.40	288.52	34.11 / 77.70
AMRUTAJAN HEALTH LTD	634.70	37.20	6.16	1834.96	548.05 / 861.40
ASTRAZENECA PHARMA IND LT	8477.50	126.44	31.19	21193.75	5000.00 / 9049.95
BLISS GVS PHARMA LTD	119.05	15.46	1.22	1254.43	92.25 / 184.95

Technicals

EMA & SMA
Resistance and Support
Price Change Analysis

Bullish Moving Averages -

Bearish Moving Averages -

5 Days 136.30
26 Days 139.10
10 Days 136.30
50 Days 145.60
12 Days 136.40
100 Days 152.10
20 Days 137.60
200 Days 151.30

135.77
PIVOT

First Resistance	140.53
Second Resistance	143.77
Third Resistance	148.53

First Support	132.53
Second Support	127.77
Third Support	124.53

RSI	47.86
MACD	-2.69
Commodity Channel Index (CCI)	-2.49

ADX	9.41
Williams % R	-52.16

Makers Laboratories Ltd. Future

Future: Price

25 May

0 100 200 300 400 500 600

Discount/Premium

25 May

0 1 2 3 4 5 6 7

Active Calls

25 May

0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul

0 500 1000 1500 2000 2500

Stock Holding

View Live Stock Screeners

Holding

Public

38.33 Promoter Holdings

61.27 FII

0.0 DII

0.38 Promoter Shares(Pledge Percentage)

0.0

Name	Category	Shares	Shares%
Kaygee Investments Private Limited	Shareholding of Promoter and Promoter Group	1025280.0	17.38
Paschim Chemicals Pvt Ltd	Shareholding of Promoter and Promoter Group	966672.0	16.38
Kaygee Laboratories Private Limited	Shareholding of Promoter and Promoter Group	846720.0	14.35
Mexin Medicaments Private Limited	Shareholding of Promoter and Promoter Group	183907.0	3.12
Tanvi Jignesh Mehta	Public Shareholding	127650.0	2.16
Premchand Godha	Shareholding of Promoter and Promoter Group	127033.0	2.15
Prashant Godha	Shareholding of Promoter and Promoter Group	122937.0	2.08
Nirmal Gigalal Jain	Shareholding of Promoter and Promoter Group	95875.0	1.62
Chandurkar Investments Private Limited	Shareholding of Promoter and Promoter Group	84411.0	1.43
Kiran Rashmin Rughani	Public Shareholding	81000.0	1.37
Usha Premchand Godha	Shareholding of Promoter and Promoter Group	57315.0	0.97
Bhawna Godha	Shareholding of Promoter and Promoter Group	42206.0	0.72
Usha M Chandurkar	Shareholding of Promoter and Promoter Group	41000.0	0.69
Sameer M Chandurkar	Shareholding of Promoter and Promoter Group	22000.0	0.37

Makers Laboratories Ltd.

Ex-Date	Dividend Amt.	Dividend Type	Record Date	Instrument Type
2019-08-01	1.0	Final	2019-08-03	Equity shares	2018-07-26	1.0	Final	2018-07-28	Equity shares	2017-07-20	1.0	Final	2017-07-22	Equity shares	2016-08-02	1.0	Final	2016-08-04	Equity shares	2015-07-28	1.0	Final	2015-07-30	Equity shares	2011-07-29	1.0	Final	2011-08-02	Equity shares	2010-08-17	1.0	Final	2010-08-19	Equity shares

Learn More About Stocks

Dr Reddy’s Denies Workforce Reduction Claims Amid Cost-Cut Rumours

Dr Reddy’s Laboratories rejects claims of reducing workforce costs by 25%, asserting no such plans or internal directives.

15 Apr, 2025 | 3 Min. read

Glenmark, Sun Pharma, Zydus Recall Drugs in US over Compliance Issues

Glenmark, Sun Pharma, and Zydus recall multiple drug batches in the US following manufacturing deviations and contamination concerns as per USFDA enforcement reports.

15 Apr, 2025 | 3 Min. read

HAL Denies Selecting PwC for R&D Benchmarking Amid Ongoing Bids

HAL clarifies no consultancy firm has been finalised for R&D benchmarking amid social media buzz about PwC. Selection process still ongoing via GeM portal.

15 Apr, 2025 | 3 Min. read

Aurobindo Pharma Gets USFDA Nod for Generic Xarelto 2.5mg Tablets

Aurobindo Pharma receives USFDA approval to launch generic Xarelto 2.5mg in Q1 FY26, targeting $447 million US market; higher strengths also gain tentative nod.

15 Apr, 2025 | 3 Min. read

IndiGo Becomes World’s Most Valuable Airline With $23.4 Billion Market Cap

IndiGo surpasses global peers to become the most valuable airline by market cap at $23.4 billion, pushing InterGlobe Aviation share price to record highs in 2025.

11 Apr, 2025 | 3 Min. read

SRF Ltd. Commissions New Agrochemical Unit in Dahej Worth Rs.239 Crore

SRF Ltd. starts new agrochemical facility in Dahej, Gujarat with Rs.239 crore investment. Phase 1 operational, full commissioning set for April 2025.

11 Apr, 2025 | 3 Min. read

Tata Motors’ JLR India Achieves Record Sales in FY25 at 6,183 Units

JLR India posts record-breaking FY25 retail sales of 6,183 units, up 40%. Defender leads growth, boosting Tata Motors share price sentiment.

11 Apr, 2025 | 4 Min. read

Biocon Gets USFDA Approval for Jobevne, Expands Oncology Portfolio

Biocon Biologics receives USFDA nod for cancer drug Jobevne, a bevacizumab biosimilar. Oncology portfolio in US grows, boosting Biocon Ltd. share price outlook.

11 Apr, 2025 | 3 Min. read